Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

NCT05188729 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.

NCT NCT05188729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05188729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
Lead sponsor
Verrica Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2022
Completion date
April 15, 2024
Enrollment
92 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma, cancer of the skin, cancer of the skin, basal cell, carcinoma, skin cancer